{"id":295571,"date":"2025-12-15T00:00:00","date_gmt":"2025-12-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0036-2023-biopharma-painful-diabetic-neuropathy-current-treatment-treatment-algorithms-claims\/"},"modified":"2026-03-31T10:23:58","modified_gmt":"2026-03-31T10:23:58","slug":"algocg0036-2025-biopharma-painful-diabetic-neuropathy-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0036-2025-biopharma-painful-diabetic-neuropathy-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)"},"content":{"rendered":"
\n

Painful diabetic neuropathy (PDN<\/abbr>) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and\/or hands. PDN<\/abbr> is managed with multiple well-established, generic treatment options including antidepressants (e.g., tricyclic antidepressants, serotonin \/ norepinephrine reuptake inhibitors), antiepileptic drugs (e.g., gabapentin), nonsteroidal anti-inflammatory drugs (NSAID<\/abbr>s), and opioid-based drugs. However, current analgesics do not offer adequate pain relief to all patients, leaving unmet need and opportunity for new options, especially novel mechanisms of action. The early PDN<\/abbr> pipeline is large and diverse, and Vertex\u2019s novel Nav1.8 inhibitor Journavx (suzetrigine) is in Phase 3 development for PDN<\/abbr>. The successful launch of a novel analgesic will require a granular understanding of treatment patterns in this crowded and highly generic market.<\/p>\n<\/div>\n

\n

QUESTIONS ANSWERED<\/strong><\/p>\n<\/div>\n

\n
    \n
  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PDN<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PDN<\/abbr> patients?<\/li>\n
  • What percentage of PDN<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n
  • What percentage of PDN<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n
  • What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<\/div>\n

    Markets covered:<\/strong> United States<\/p>\n

    Key companies:<\/strong> AbbVie, Almatica, Aucta, Averitas, Azurity, BioDelivery Sciences International, Collegium Pharmaceuticals, Kowa, Protega Pharmaceuticals, Sumitomo Pharma, Vertex, Viatris<\/p>\n

    Key drugs:<\/strong> Gabapentin (Neurontin, generics), tramadol, duloxetine (Cymbalta, generics), pregabalin (Lyrica, generics), Motpoly XR<\/abbr>, other antidepressants (e.g., amitriptyline, citalopram, escitalopram), other AEDS (e.g., carbamazepine, topiramate), oral NSAID<\/abbr>s, opioid analgesics (e.g., Belbuca, RoxyBond, Xtampza ER<\/abbr>), Qutenza, Gralise, Horizant, Nucynta, ZTlido, Journavx<\/p>\n

    Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n

    PRODUCT DESCRIPTION<\/strong><\/p>\n

    \n

    Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n

    \n
      \n
    • Understand patient flow between lines of therapy.<\/li>\n
    • Evaluate your brand share against competitors.<\/li>\n
    • Accurately assess your source of business.<\/li>\n
    • Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n

      Product enhancement<\/strong><\/p>\n

      Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-295571","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-neuropathy","biopharma-therapy-areas-painful-diabetic-neuropathy","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295571\/revisions"}],"predecessor-version":[{"id":571403,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295571\/revisions\/571403"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}